Angelman syndrome (AS) is a rare neurogenetic disorder caused by a loss of function of the UBE3A gene on chromosome 15. It affects roughly one in 15,000 children — approximately 500,000 people worldwide. Because AS shares characteristics with autism, cerebral palsy, and Prader-Willi syndrome, it is frequently misdiagnosed, and many families wait years for an accurate answer.
AS affects development in significant ways — including speech, movement, balance, and sleep. Most children with AS experience developmental delays and limited expressive speech, and many face recurrent seizures and gastrointestinal challenges. And yet, despite all of this, individuals with Angelman syndrome are known for their bright, joyful, and social nature. Maddie is a perfect example.
The good news: research is accelerating. There is now an active pipeline of therapies and clinical trials targeting Angelman syndrome — including gene therapy, protein replacement, and paternal gene activation approaches. Scientists are no longer asking if a treatment will exist. They're asking when.
